{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:30:40Z","timestamp":1793745040016,"version":"4.6.1"},"reference-count":287,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41573-026-01459-7","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:02:22Z","timestamp":1780488142000},"page":"757-778","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Towards mRNA therapeutics 2.0"],"prefix":"10.1038","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2759-8378","authenticated-orcid":false,"given":"Kenneth R.","family":"Chien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4040-5761","authenticated-orcid":false,"given":"Kylie S.","family":"Foo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1109-778X","authenticated-orcid":false,"given":"Nevin","family":"Witman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"1459_CR1","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.4161\/hv.25181","volume":"9","author":"K-J Kallen","year":"2013","unstructured":"Kallen, K.-J. et al. A novel, disruptive vaccination technology: self-adjuvanted RNActive\u00ae vaccines. Hum. Vaccin. Immunother.\u00a09, 2263\u20132276 (2013).","journal-title":"Hum. Vaccin. Immunother."},{"key":"1459_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1459_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1146\/annurev-med-042420-112725","volume":"73","author":"MJ Hogan","year":"2022","unstructured":"Hogan, M. J. & Pardi, N. mRNA vaccines in the COVID-19 pandemic and beyond. Annu. Rev. Med. 73, 17\u201339 (2022).","journal-title":"Annu. Rev. Med."},{"key":"1459_CR4","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1080\/21645515.2020.1829899","volume":"17","author":"AO Aliprantis","year":"2021","unstructured":"Aliprantis, A. O. et al. A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults. Hum. Vacc. Immunother.\u00a017, 1248\u20131261 (2021).","journal-title":"Hum. Vacc. Immunother."},{"key":"1459_CR5","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","volume":"389","author":"E Wilson","year":"2023","unstructured":"Wilson, E. et al. Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults. N. Engl. J. Med. 389, 2233\u20132244 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1459_CR6","doi-asserted-by":"publisher","first-page":"e647","DOI":"10.1093\/infdis\/jiae081","volume":"230","author":"CA Shaw","year":"2024","unstructured":"Shaw, C. A. et al. Safety and immunogenicity of an mRNA-based RSV vaccine including a 12-month booster in a phase 1 clinical trial in healthy older adults. J. Infect. Dis. 230, e647\u2013e656 (2024).","journal-title":"J. Infect. Dis."},{"key":"1459_CR7","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1126\/science.abm0271","volume":"378","author":"CP Arevalo","year":"2022","unstructured":"Arevalo, C. P. et al. A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes. Science 378, 899\u2013904 (2022).","journal-title":"Science"},{"key":"1459_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39376-7","volume":"14","author":"IT Lee","year":"2023","unstructured":"Lee, I. T. et al. Safety and immunogenicity of a phase 1\/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis. Nat. Commun. 14, 3631 (2023).","journal-title":"Nat. Commun."},{"key":"1459_CR9","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/infdis\/jiad593","volume":"230","author":"X Hu","year":"2024","unstructured":"Hu, X. et al. Human cytomegalovirus mRNA-1647 vaccine candidate elicits potent and broad neutralization and higher antibody-dependent cellular cytotoxicity responses than the gB\/MF59 vaccine. J. Infect. Dis. 230, 455\u2013466 (2024).","journal-title":"J. Infect. Dis."},{"key":"1459_CR10","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01603-23","volume":"98","author":"K Wu","year":"2024","unstructured":"Wu, K. et al. Characterization of humoral and cellular immunologic responses to an mRNA-based human cytomegalovirus vaccine from a phase 1 trial of healthy adults. J. Virol. 98, e01603-23 (2024).","journal-title":"J. Virol."},{"key":"1459_CR11","doi-asserted-by":"publisher","first-page":"e668","DOI":"10.1093\/infdis\/jiae114","volume":"230","author":"C Fierro","year":"2024","unstructured":"Fierro, C. et al. Safety and immunogenicity of a messenger RNA-based cytomegalovirus vaccine in healthy adults: results from a phase 1 randomized clinical trial. J. Infect. Dis. 230, e668\u2013e678 (2024).","journal-title":"J. Infect. Dis."},{"key":"1459_CR12","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S0140-6736(23)02444-3","volume":"403","author":"H Parhiz","year":"2024","unstructured":"Parhiz, H., Atochina-Vasserman, E. N. & Weissman, D. mRNA-based therapeutics: looking beyond COVID-19 vaccines. Lancet 403, 1192\u20131204 (2024).","journal-title":"Lancet"},{"key":"1459_CR13","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/s41587-022-01491-z","volume":"40","author":"E Rohner","year":"2022","unstructured":"Rohner, E., Yang, R., Foo, K. S., Goedel, A. & Chien, K. R. Unlocking the promise of mRNA therapeutics. Nat. Biotechnol. 40, 1586\u20131600 (2022).","journal-title":"Nat. Biotechnol."},{"key":"1459_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41573-023-00827-x","volume":"23","author":"M Metkar","year":"2024","unstructured":"Metkar, M., Pepin, C. S. & Moore, M. J. Tailor made: the art of therapeutic mRNA design. Nat. Rev. Drug. Discov. 23, 67\u201383 (2024).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1459_CR15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2307796121","volume":"121","author":"CA Tsuchida","year":"2024","unstructured":"Tsuchida, C. A., Wasko, K. M., Hamilton, J. R. & Doudna, J. A. Targeted nonviral delivery of genome editors in vivo. Proc. Natl Acad. Sci. USA 121, e2307796121 (2024).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1459_CR16","doi-asserted-by":"publisher","first-page":"103505","DOI":"10.1016\/j.drudis.2023.103505","volume":"28","author":"MCP Mendon\u00e7a","year":"2023","unstructured":"Mendon\u00e7a, M. C. P., Kont, A., Kowalski, P. S. & O\u2019Driscoll, C. M. Design of lipid-based nanoparticles for delivery of therapeutic nucleic acids. Drug Discov. Today 28, 103505 (2023).","journal-title":"Drug Discov. Today"},{"key":"1459_CR17","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.4c00925","author":"Y Yuan","year":"2025","unstructured":"Yuan, Y. et al. Intelligent design of lipid nanoparticles for enhanced gene therapeutics. Mol. Pharm. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c00925 (2025).","journal-title":"Mol. Pharm."},{"key":"1459_CR18","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/d41586-021-02483-w","volume":"597","author":"E Dolgin","year":"2021","unstructured":"Dolgin, E. The tangled history of mRNA vaccines. Nature 597, 318\u2013324 (2021).","journal-title":"Nature"},{"key":"1459_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-024-02002-z","volume":"9","author":"Y Shi","year":"2024","unstructured":"Shi, Y., Shi, M., Wang, Y. & You, J. Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications. Sig Transduct. Target. Ther. 9, 1\u201343 (2024).","journal-title":"Sig Transduct. Target. Ther."},{"key":"1459_CR20","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1056\/NEJMcibr2009737","volume":"382","author":"DH Fuller","year":"2020","unstructured":"Fuller, D. H. & Berglund, P. Amplifying RNA vaccine development. N. Engl. J. Med. 382, 2469\u20132471 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1459_CR21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines\u2014a new era in vaccinology. Nat. Rev. Drug. Discov. 17, 261\u2013279 (2018).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1459_CR22","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.3390\/ijms24032700","volume":"24","author":"V Gote","year":"2023","unstructured":"Gote, V. et al. A comprehensive review of mRNA vaccines. Int. J. Mol. Sci. 24, 2700 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1459_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s43586-023-00246-7","volume":"3","author":"S Chen","year":"2023","unstructured":"Chen, S. et al. Nanotechnology-based mRNA vaccines. Nat. Rev. Methods Primers 3, 1\u201319 (2023).","journal-title":"Nat. Rev. Methods Primers"},{"key":"1459_CR24","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","volume":"23","author":"K Karik\u00f3","year":"2005","unstructured":"Karik\u00f3, K., Buckstein, M., Ni, H. & Weissman, D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165\u2013175 (2005).","journal-title":"Immunity"},{"key":"1459_CR25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/bs.ircmb.2022.04.010","volume":"372","author":"I G\u00f3mez-Aguado","year":"2022","unstructured":"G\u00f3mez-Aguado, I. et al. mRNA delivery technologies: toward clinical translation. Int. Rev. Cell Mol. Biol. 372, 207\u2013293 (2022).","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"1459_CR26","doi-asserted-by":"publisher","first-page":"102721","DOI":"10.1016\/j.omtn.2025.102721","volume":"36","author":"MA Ige","year":"2025","unstructured":"Ige, M. A. et al. mRNA therapeutics: transforming medicine through innovation in design, delivery, and disease treatment. Mol. Ther. Nucleic Acids 36, 102721 (2025).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1459_CR27","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S0955-0674(98)80150-6","volume":"10","author":"N Sonenberg","year":"1998","unstructured":"Sonenberg, N. & Gingras, A.-C. The mRNA 5\u2032 cap-binding protein eIF4E and control of cell growth. Curr. Opin. Cell Biol. 10, 268\u2013275 (1998).","journal-title":"Curr. Opin. Cell Biol."},{"key":"1459_CR28","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1261\/rna.7380904","volume":"10","author":"E Grudzien","year":"2004","unstructured":"Grudzien, E. et al. Novel cap analogs for in vitro synthesis of mRNAs with high translational efficiency. RNA 10, 1479\u20131487 (2004).","journal-title":"RNA"},{"key":"1459_CR29","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/wrna.15","volume":"1","author":"Y Li","year":"2010","unstructured":"Li, Y. & Kiledjian, M. Regulation of mRNA decapping. WIREs RNA 1, 253\u2013265 (2010).","journal-title":"WIREs RNA"},{"key":"1459_CR30","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.4155\/fmc.13.96","volume":"5","author":"M Ziemniak","year":"2013","unstructured":"Ziemniak, M., Strenkowska, M., Kowalska, J. & Jemielity, J. Potential therapeutic applications of RNA cap analogs. Future Med. Chem. 5, 1141\u20131172 (2013).","journal-title":"Future Med. Chem."},{"key":"1459_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2025.102456","volume":"36","author":"ZF Mandell","year":"2025","unstructured":"Mandell, Z. F. et al. CleanCap M6 inhibits decapping of exogenously delivered IVT mRNA. Mol. Ther. Nucleic Acids 36, 102456 (2025).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1459_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38244-8","volume":"14","author":"M Inagaki","year":"2023","unstructured":"Inagaki, M. et al. Cap analogs with a hydrophobic photocleavable tag enable facile purification of fully capped mRNA with various cap structures. Nat. Commun. 14, 2657 (2023).","journal-title":"Nat. Commun."},{"key":"1459_CR33","first-page":"1486","volume":"7","author":"J Stepinski","year":"2001","unstructured":"Stepinski, J., Waddell, C., Stolarski, R., Darzynkiewicz, E. & Rhoads, R. E. Synthesis and properties of mRNAs containing the novel \u2018anti-reverse\u2019 cap analogs 7-methyl(3\u2032-O-methyl)GpppG and 7-methyl (3\u2032-deoxy)GpppG. RNA 7, 1486\u20131495 (2001).","journal-title":"RNA"},{"key":"1459_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/cpz1.39","volume":"1","author":"JM Henderson","year":"2021","unstructured":"Henderson, J. M. et al. Cap 1 Messenger RNA synthesis with co-transcriptional CleanCap\u00ae analog by in vitro transcription. Curr. Protoc. 1, e39 (2021).","journal-title":"Curr. Protoc."},{"key":"1459_CR35","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.bbrc.2005.12.105","volume":"340","author":"M Mockey","year":"2006","unstructured":"Mockey, M. et al. mRNA transfection of dendritic cells: synergistic effect of ARCA mRNA capping with poly(A) chains in cis and in trans for a high protein expression level. Biochem. Biophys. Res. Commun. 340, 1062\u20131068 (2006).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1459_CR36","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1016\/j.ymthe.2025.03.060","volume":"33","author":"IC Casmil","year":"2025","unstructured":"Casmil, I. C. et al. The advent of clinical self-amplifying RNA vaccines. Mol. Ther. 33, 2565\u20132582 (2025).","journal-title":"Mol. Ther."},{"key":"1459_CR37","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/s41594-020-0465-x","volume":"27","author":"L Jia","year":"2020","unstructured":"Jia, L. et al. Decoding mRNA translatability and stability from the 5\u2032 UTR. Nat. Struct. Mol. Biol. 27, 814\u2013821 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1459_CR38","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41587-019-0164-5","volume":"37","author":"PJ Sample","year":"2019","unstructured":"Sample, P. J. et al. Human 5\u2032 UTR design and variant effect prediction from a massively parallel translation assay. Nat. Biotechnol. 37, 803\u2013809 (2019).","journal-title":"Nat. Biotechnol."},{"key":"1459_CR39","doi-asserted-by":"publisher","first-page":"vbaf134","DOI":"10.1093\/bioadv\/vbaf134","volume":"5","author":"S Barazandeh","year":"2024","unstructured":"Barazandeh, S., Ozden, F., Hincer, A., Seker, U. O. S. & Cicek, A. E. UTRGAN: learning to generate 5\u2032 UTR sequences for optimized translation efficiency and gene expression. Bioinforma. Adv. 5, vbaf134 (2024).","journal-title":"Bioinforma. Adv."},{"key":"1459_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202407013","volume":"11","author":"Y Yang","year":"2024","unstructured":"Yang, Y. et al. Deciphering 3\u2032UTR mediated gene regulation using interpretable deep representation learning. Adv. Sci. 11, e2407013 (2024).","journal-title":"Adv. Sci."},{"key":"1459_CR41","doi-asserted-by":"publisher","unstructured":"Morrow, A. K. et al. ML-driven design of 3\u2032 UTRs for mRNA stability. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2024.10.07.616676 (2024).","DOI":"10.1101\/2024.10.07.616676"},{"key":"1459_CR42","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.ymthe.2018.12.011","volume":"27","author":"AG Orlandini Von Niessen","year":"2019","unstructured":"Orlandini Von Niessen, A. G. et al. Improving mRNA-based therapeutic gene delivery by expression-augmenting 3\u2032 UTRs identified by cellular library screening. Mol. Ther. 27, 824\u2013836 (2019).","journal-title":"Mol. Ther."},{"key":"1459_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2025.102485","volume":"36","author":"X Ma","year":"2025","unstructured":"Ma, X. et al. Enhancing mRNA translation efficiency by introducing sequence optimized AU-rich elements in 3\u2032 UTR via HuR anchorage. Mol. Ther. Nucleic Acids 36, 102485 (2025).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1459_CR44","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.omtm.2020.03.019","volume":"17","author":"N Sultana","year":"2020","unstructured":"Sultana, N. et al. Optimization of 5\u2032 untranslated region of modified mRNA for use in cardiac or hepatic ischemic injury. Mol. Ther. Methods Clin. Dev. 17, 622\u2013633 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1459_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-64894-x","volume":"16","author":"Y Li","year":"2025","unstructured":"Li, Y. et al. Deep generative optimization of mRNA codon sequences for enhanced mRNA translation and therapeutic efficacy. Nat. Commun. 16, 9957 (2025).","journal-title":"Nat. Commun."},{"key":"1459_CR46","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41586-023-06127-z","volume":"621","author":"H Zhang","year":"2023","unstructured":"Zhang, H. et al. Algorithm for optimized mRNA design improves stability and immunogenicity. Nature 621, 396\u2013403 (2023).","journal-title":"Nature"},{"key":"1459_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28776-w","volume":"13","author":"K Leppek","year":"2022","unstructured":"Leppek, K. et al. Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics. Nat. Commun. 13, 1536 (2022).","journal-title":"Nat. Commun."},{"key":"1459_CR48","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrm.2017.91","volume":"19","author":"G Hanson","year":"2018","unstructured":"Hanson, G. & Coller, J. Codon optimality, bias and usage in translation and mRNA decay. Nat. Rev. Mol. Cell Biol. 19, 20\u201330 (2018).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1459_CR49","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1261\/rna.073239.119","volume":"25","author":"A Narula","year":"2019","unstructured":"Narula, A., Ellis, J., Taliaferro, J. M. & Rissland, O. S. Coding regions affect mRNA stability in human cells. RNA 25, 1751\u20131764 (2019).","journal-title":"RNA"},{"key":"1459_CR50","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41577-021-00608-w","volume":"21","author":"K Karik\u00f3","year":"2021","unstructured":"Karik\u00f3, K. Modified uridines are the key to a successful message. Nat. Rev. Immunol. 21, 619\u2013619 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"1459_CR51","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/mt.2008.200","volume":"16","author":"K Karik\u00f3","year":"2008","unstructured":"Karik\u00f3, K. et al. Incorporation of pseudouridine Into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 16, 1833\u20131840 (2008).","journal-title":"Mol. Ther."},{"key":"1459_CR52","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1021\/acscentsci.1c00197","volume":"7","author":"KD Nance","year":"2021","unstructured":"Nance, K. D. & Meier, J. L. Modifications in an emergency: the role of N1-methylpseudouridine in COVID-19 vaccines. ACS Cent. Sci. 7, 748\u2013756 (2021).","journal-title":"ACS Cent. Sci."},{"key":"1459_CR53","unstructured":"Schrum, J. P., Siddiqi, S. & Ejebe, K. Ribonucleic acids containing N1-methyl-pseudouracils and uses thereof. European Patent EP2622064B1 (18 May 2022)."},{"key":"1459_CR54","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1101\/gr.278870.123","volume":"34","author":"S Li","year":"2024","unstructured":"Li, S. et al. CodonBERT large language model for mRNA vaccines. Genome Res. 34, 1027\u20131035 (2024).","journal-title":"Genome Res."},{"key":"1459_CR55","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/s42256-025-01047-1","volume":"7","author":"BP De Almeida","year":"2025","unstructured":"De Almeida, B. P. et al. A multimodal conversational agent for DNA, RNA and protein tasks. Nat. Mach. Intell. 7, 928\u2013941 (2025).","journal-title":"Nat. Mach. Intell."},{"key":"1459_CR56","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/mt.2015.103","volume":"23","author":"A Thess","year":"2015","unstructured":"Thess, A. et al. Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol. Ther. 23, 1456\u20131464 (2015).","journal-title":"Mol. Ther."},{"key":"1459_CR57","doi-asserted-by":"publisher","first-page":"7792","DOI":"10.1093\/nar\/gkae510","volume":"52","author":"N Biziaev","year":"2024","unstructured":"Biziaev, N. et al. The impact of mRNA poly(A) tail length on eukaryotic translation stages. Nucleic Acids Res. 52, 7792\u20137808 (2024).","journal-title":"Nucleic Acids Res."},{"key":"1459_CR58","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1016\/j.celrep.2016.10.066","volume":"17","author":"JAW Stowell","year":"2016","unstructured":"Stowell, J. A. W. et al. Reconstitution of targeted deadenylation by the Ccr4-Not complex and the YTH domain protein Mmi1. Cell Rep. 17, 1978\u20131989 (2016).","journal-title":"Cell Rep."},{"key":"1459_CR59","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41580-021-00417-y","volume":"23","author":"LA Passmore","year":"2022","unstructured":"Passmore, L. A. & Coller, J. Roles of mRNA poly(A) tails in regulation of eukaryotic gene expression. Nat. Rev. Mol. Cell Biol. 23, 93\u2013106 (2022).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1459_CR60","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.66493","volume":"10","author":"K Xiang","year":"2021","unstructured":"Xiang, K. & Bartel, D. P. The molecular basis of coupling between poly(A)-tail length and translational efficiency. eLife 10, e66493 (2021).","journal-title":"eLife"},{"key":"1459_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2016.21","volume":"5","author":"AE Grier","year":"2016","unstructured":"Grier, A. E. et al. pEVL: a linear plasmid for generating mRNA IVT templates with extended encoded poly(A) sequences. Mol. Ther. Nucleic Acids 5, e306 (2016).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1459_CR62","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41587-024-02174-7","volume":"43","author":"H Chen","year":"2025","unstructured":"Chen, H. et al. Branched chemically modified poly(A) tails enhance the translation capacity of mRNA. Nat. Biotechnol. 43, 194\u2013203 (2025).","journal-title":"Nat. Biotechnol."},{"key":"1459_CR63","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1021\/acschembio.1c00569","volume":"17","author":"A Aditham","year":"2022","unstructured":"Aditham, A. et al. Chemically modified mocRNAs for highly efficient protein expression in mammalian cells. ACS Chem. Biol. 17, 3352\u20133366 (2022).","journal-title":"ACS Chem. Biol."},{"key":"1459_CR64","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.omtn.2022.10.003","volume":"30","author":"CY Li","year":"2022","unstructured":"Li, C. Y. et al. Cytidine-containing tails robustly enhance and prolong protein production of synthetic mRNA in cell and in vivo. Mol. Ther. Nucleic Acids 30, 300\u2013310 (2022).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1459_CR65","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/s41587-024-02424-8","volume":"43","author":"B Liu","year":"2025","unstructured":"Liu, B. & Pan, T. Building better mRNA for therapeutics. Nat. Biotechnol. 43, 1058\u20131060 (2025).","journal-title":"Nat. Biotechnol."},{"key":"1459_CR66","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","volume":"25","author":"PR Cullis","year":"2017","unstructured":"Cullis, P. R. & Hope, M. J. Lipid nanoparticle systems for enabling gene therapies. Mol. Ther. 25, 1467\u20131475 (2017).","journal-title":"Mol. Ther."},{"key":"1459_CR67","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078\u20131094 (2021).","journal-title":"Nat. Rev. Mater."},{"key":"1459_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120586","volume":"601","author":"L Schoenmaker","year":"2021","unstructured":"Schoenmaker, L. et al. mRNA\u2013lipid nanoparticle COVID-19 vaccines: structure and stability. Int. J. Pharm. 601, 120586 (2021).","journal-title":"Int. J. Pharm."},{"key":"1459_CR69","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.4161\/rna.22269","volume":"9","author":"T Schlake","year":"2012","unstructured":"Schlake, T., Thess, A., Fotin-Mleczek, M. & Kallen, K.-J. Developing mRNA-vaccine technologies. RNA Biol. 9, 1319\u20131330 (2012).","journal-title":"RNA Biol."},{"key":"1459_CR70","doi-asserted-by":"publisher","first-page":"9015","DOI":"10.1007\/s12274-024-6978-6","volume":"17","author":"X Hou","year":"2024","unstructured":"Hou, X., Shi, J. & Xiao, Y. mRNA medicine: recent progresses in chemical modification, design, and engineering. Nano Res. 17, 9015\u20139030 (2024).","journal-title":"Nano Res."},{"key":"1459_CR71","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41578-022-00529-7","volume":"8","author":"SA Dilliard","year":"2023","unstructured":"Dilliard, S. A. & Siegwart, D. J. Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs. Nat. Rev. Mater. 8, 282\u2013300 (2023).","journal-title":"Nat. Rev. Mater."},{"key":"1459_CR72","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nbt.3802","volume":"35","author":"SF Dowdy","year":"2017","unstructured":"Dowdy, S. F. Overcoming cellular barriers for RNA therapeutics. Nat. Biotechnol. 35, 222\u2013229 (2017).","journal-title":"Nat. Biotechnol."},{"key":"1459_CR73","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/nri2448","volume":"8","author":"DM Mosser","year":"2008","unstructured":"Mosser, D. M. & Edwards, J. P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8, 958\u2013969 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"1459_CR74","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.apsb.2022.07.013","volume":"13","author":"Q Nie","year":"2023","unstructured":"Nie, Q. et al. Pathologically triggered in situ aggregation of nanoparticles for inflammation-targeting amplification and therapeutic potentiation. Acta Pharm. Sin. B 13, 390\u2013409 (2023).","journal-title":"Acta Pharm. Sin. B"},{"key":"1459_CR75","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0014-5793(99)00364-6","volume":"448","author":"EL Romero","year":"1999","unstructured":"Romero, E. L., Morilla, M.-J., Regts, J., Koning, G. A. & Scherphof, G. L. On the mechanism of hepatic transendothelial passage of large liposomes. FEBS Lett. 448, 193\u2013196 (1999).","journal-title":"FEBS Lett."},{"key":"1459_CR76","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abf4398","volume":"7","author":"M Kim","year":"2021","unstructured":"Kim, M. et al. Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver. Sci. Adv. 7, eabf4398 (2021).","journal-title":"Sci. Adv."},{"key":"1459_CR77","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41573-024-00977-6","volume":"23","author":"PR Cullis","year":"2024","unstructured":"Cullis, P. R. & Felgner, P. L. The 60-year evolution of lipid nanoparticles for nucleic acid delivery. Nat. Rev. Drug. Discov. 23, 709\u2013722 (2024).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1459_CR78","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1038\/s12276-023-01086-x","volume":"55","author":"Y Lee","year":"2023","unstructured":"Lee, Y., Jeong, M., Park, J., Jung, H. & Lee, H. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics. Exp. Mol. Med. 55, 2085\u20132096 (2023).","journal-title":"Exp. Mol. Med."},{"key":"1459_CR79","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1038\/s41551-024-01256-w","volume":"8","author":"N Chaudhary","year":"2024","unstructured":"Chaudhary, N. et al. Amine headgroups in ionizable lipids drive immune responses to lipid nanoparticles by binding to the receptors TLR4 and CD1d. Nat. Biomed. Eng. 8, 1483\u20131498 (2024).","journal-title":"Nat. Biomed. Eng."},{"key":"1459_CR80","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/cr.2013.112","volume":"23","author":"KO Lui","year":"2013","unstructured":"Lui, K. O. et al. Driving vascular endothelial cell fate of human multipotent Isl1+ heart progenitors with VEGF modified mRNA. Cell Res. 23, 1172\u20131186 (2013).","journal-title":"Cell Res."},{"key":"1459_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00760-5","volume":"8","author":"C Xie","year":"2023","unstructured":"Xie, C., Yao, R. & Xia, X. The advances of adjuvants in mRNA vaccines. npj Vaccines 8, 162 (2023).","journal-title":"npj Vaccines"},{"key":"1459_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01643-1","author":"N Warne","year":"2023","unstructured":"Warne, N. et al. Delivering 3\u2009billion doses of Comirnaty in 2021. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-022-01643-1 (2023).","journal-title":"Nat. Biotechnol."},{"key":"1459_CR83","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/psp4.12516","volume":"9","author":"J Almquist","year":"2020","unstructured":"Almquist, J. et al. Model-based analysis reveals a sustained and dose-dependent acceleration of wound healing by VEGF-A mRNA (AZD8601). CPT Pharmacom Syst. Pharma 9, 384\u2013394 (2020).","journal-title":"CPT Pharmacom Syst. Pharma"},{"key":"1459_CR84","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.omtm.2018.04.003","volume":"9","author":"L Carlsson","year":"2018","unstructured":"Carlsson, L. et al. Biocompatible, purified VEGF-A mRNA improves cardiac function after intracardiac injection 1\u2009week post-myocardial infarction in swine. Mol. Ther. Methods Clin. Dev. 9, 330\u2013346 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1459_CR85","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.scr.2014.06.007","volume":"13","author":"KO Lui","year":"2014","unstructured":"Lui, K. O., Zangi, L. & Chien, K. R. Cardiovascular regenerative therapeutics via synthetic paracrine factor modified mRNA. Stem Cell Res. 13, 693\u2013704 (2014).","journal-title":"Stem Cell Res."},{"key":"1459_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-35570-6","volume":"8","author":"N Sun","year":"2018","unstructured":"Sun, N. et al. Modified VEGF-A mRNA induces sustained multifaceted microvascular response and accelerates diabetic wound healing. Sci. Rep. 8, 17509 (2018).","journal-title":"Sci. Rep."},{"key":"1459_CR87","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/nbt.2682","volume":"31","author":"L Zangi","year":"2013","unstructured":"Zangi, L. et al. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat. Biotechnol. 31, 898\u2013907 (2013).","journal-title":"Nat. Biotechnol."},{"key":"1459_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08852-4","volume":"10","author":"L-M Gan","year":"2019","unstructured":"Gan, L.-M. et al. Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes. Nat. Commun. 10, 871 (2019).","journal-title":"Nat. Commun."},{"key":"1459_CR89","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41573-021-00355-6","volume":"21","author":"A Coll\u00e9n","year":"2022","unstructured":"Coll\u00e9n, A. et al. VEGFA mRNA for regenerative treatment of heart failure. Nat. Rev. Drug Discov. 21, 79\u201380 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1459_CR90","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.ymthe.2022.11.017","volume":"31","author":"V Anttila","year":"2023","unstructured":"Anttila, V. et al. Direct intramyocardial injection of VEGF mRNA in patients undergoing coronary artery bypass grafting. Mol. Ther. 31, 866\u2013874 (2023).","journal-title":"Mol. Ther."},{"key":"1459_CR91","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jconrel.2019.08.014","volume":"310","author":"Z Yu","year":"2019","unstructured":"Yu, Z. et al. Cell-mediated delivery of VEGF modified mRNA enhances blood vessel regeneration and ameliorates murine critical limb ischemia. J. Control. Rel. 310, 103\u2013114 (2019).","journal-title":"J. Control. Rel."},{"key":"1459_CR92","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ymthe.2022.08.012","volume":"31","author":"X Ai","year":"2023","unstructured":"Ai, X. et al. Transient secretion of VEGF protein from transplanted hiPSC-CMs enhances engraftment and improves rat heart function post MI. Mol. Ther. 31, 211\u2013229 (2023).","journal-title":"Mol. Ther."},{"key":"1459_CR93","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1161\/HYPERTENSIONAHA.119.13469","volume":"74","author":"JE Engel","year":"2019","unstructured":"Engel, J. E., Williams, E., Williams, M. L., Bidwell, G. L. & Chade, A. R. Targeted VEGF (vascular endothelial growth factor) therapy induces long-term renal recovery in chronic kidney disease via macrophage polarization. Hypertension 74, 1113\u20131123 (2019).","journal-title":"Hypertension"},{"key":"1459_CR94","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s42003-020-01606-9","volume":"4","author":"Y Geng","year":"2021","unstructured":"Geng, Y. et al. BMP-2 and VEGF-A modRNAs in collagen scaffold synergistically drive bone repair through osteogenic and angiogenic pathways. Commun. Biol. 4, 82 (2021).","journal-title":"Commun. Biol."},{"key":"1459_CR95","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1186\/s13287-020-02008-8","volume":"11","author":"F Yu","year":"2020","unstructured":"Yu, F. et al. Human adipose-derived stem cells enriched with VEGF-modified mRNA promote angiogenesis and long-term graft survival in a fat graft transplantation model. Stem Cell Res. Ther. 11, 490 (2020).","journal-title":"Stem Cell Res. Ther."},{"key":"1459_CR96","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1002\/psp4.13142","volume":"13","author":"I Liric Rajlic","year":"2024","unstructured":"Liric Rajlic, I. et al. Translational kinetic-pharmacodynamics of mRNA-6231, an investigational mRNA therapeutic encoding mutein interleukin-2. CPT Pharmacom Syst. Pharma 13, 1067\u20131078 (2024).","journal-title":"CPT Pharmacom Syst. Pharma"},{"key":"1459_CR97","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41435-023-00221-y","volume":"24","author":"V Lykhopiy","year":"2023","unstructured":"Lykhopiy, V., Malviya, V., Humblet-Baron, S. & Schlenner, S. M. IL-2 immunotherapy for targeting regulatory T cells in autoimmunity. Genes. Immun. 24, 248\u2013262 (2023).","journal-title":"Genes. Immun."},{"key":"1459_CR98","doi-asserted-by":"publisher","first-page":"104539","DOI":"10.1016\/j.ebiom.2023.104539","volume":"90","author":"ME Raeber","year":"2023","unstructured":"Raeber, M. E., Sahin, D., Karakus, U. & Boyman, O. A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases. eBioMedicine 90, 104539 (2023).","journal-title":"eBioMedicine"},{"key":"1459_CR99","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.coi.2020.07.004","volume":"67","author":"N Mikami","year":"2020","unstructured":"Mikami, N., Kawakami, R. & Sakaguchi, S. New Treg cell-based therapies of autoimmune diseases: towards antigen-specific immune suppression. Curr. Opin. Immunol. 67, 36\u201341 (2020).","journal-title":"Curr. Opin. Immunol."},{"key":"1459_CR100","first-page":"2009","volume":"50","author":"MW Konrad","year":"1990","unstructured":"Konrad, M. W. et al. Pharmacokinetics of recombinant interleukin 2 in humans. Cancer Res. 50, 2009\u20132017 (1990).","journal-title":"Cancer Res."},{"key":"1459_CR101","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41573-024-01089-x","volume":"24","author":"CM Wardell","year":"2025","unstructured":"Wardell, C. M., Boardman, D. A. & Levings, M. K. Harnessing the biology of regulatory T cells to treat disease. Nat. Rev. Drug. Discov. 24, 93\u2013111 (2025).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1459_CR102","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31130-9","volume":"13","author":"S De Picciotto","year":"2022","unstructured":"De Picciotto, S. et al. Selective activation and expansion of regulatory T cells using lipid encapsulated mRNA encoding a long-acting IL-2 mutein. Nat. Commun. 13, 3866 (2022).","journal-title":"Nat. Commun."},{"key":"1459_CR103","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1038\/s41388-024-03066-5","volume":"43","author":"J Zeng","year":"2024","unstructured":"Zeng, J. et al. Antitumor activity of Z15-0-2, a bispecific nanobody targeting PD-1 and CTLA-4. Oncogene 43, 2244\u20132252 (2024).","journal-title":"Oncogene"},{"key":"1459_CR104","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1158\/1538-7445.AM2024-1368","volume":"84","author":"E Chung","year":"2024","unstructured":"Chung, E. et al. Abstract 1368: Novel mRNA encoding anti-PD-L1 monoclonal antibodies for cancer immunotherapy. Cancer Res. 84, 1368 (2024).","journal-title":"Cancer Res."},{"key":"1459_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14630","volume":"8","author":"N Pardi","year":"2017","unstructured":"Pardi, N. et al. Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat. Commun. 8, 14630 (2017).","journal-title":"Nat. Commun."},{"key":"1459_CR106","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/nm.4356","volume":"23","author":"CR Stadler","year":"2017","unstructured":"Stadler, C. R. et al. Elimination of large tumors in mice by mRNA-encoded bispecific antibodies. Nat. Med. 23, 815\u2013817 (2017).","journal-title":"Nat. Med."},{"key":"1459_CR107","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.3389\/fimmu.2019.02920","volume":"10","author":"D De Vlieger","year":"2019","unstructured":"De Vlieger, D. et al. Selective engagement of Fc\u03b3RIV by a M2e-specific single domain antibody construct protects against influenza A virus infection. Front. Immunol. 10, 2920 (2019).","journal-title":"Front. Immunol."},{"key":"1459_CR108","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.omtn.2020.04.015","volume":"20","author":"L Van Hoecke","year":"2020","unstructured":"Van Hoecke, L. et al. mRNA encoding a bispecific single domain antibody construct protects against influenza A virus infection in mice. Mol. Ther. Nucleic Acids 20, 777\u2013787 (2020).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1459_CR109","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1200\/JCO.2025.43.16_suppl.2501","volume":"43","author":"TA Yap","year":"2025","unstructured":"Yap, T. A. et al. First-in-human phase I\/II trial evaluating BNT142, a first-in-class mRNA encoded, bispecific antibody targeting Claudin 6 (CLDN6) and CD3, in patients (pts) with CLDN6-positive advanced solid tumors. J. Clin. Oncol. 43, 2501 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1459_CR110","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s43556-024-00210-1","volume":"5","author":"H Aboul-Ella","year":"2024","unstructured":"Aboul-Ella, H. et al. Monoclonal antibodies: from magic bullet to precision weapon. Mol. Biomed. 5, 47 (2024).","journal-title":"Mol. Biomed."},{"key":"1459_CR111","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04553-1","volume":"21","author":"Y Zhao","year":"2023","unstructured":"Zhao, Y., Gan, L., Ke, D., Chen, Q. & Fu, Y. Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy. J. Transl. Med. 21, 693 (2023).","journal-title":"J. Transl. Med."},{"key":"1459_CR112","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-019-1804-8","volume":"17","author":"L Van Hoecke","year":"2019","unstructured":"Van Hoecke, L. & Roose, K. How mRNA therapeutics are entering the monoclonal antibody field. J. Transl. Med. 17, 54 (2019).","journal-title":"J. Transl. Med."},{"key":"1459_CR113","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-021-01573-6","volume":"27","author":"A August","year":"2021","unstructured":"August, A. et al. A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus. Nat. Med. 27, 2224\u20132233 (2021).","journal-title":"Nat. Med."},{"key":"1459_CR114","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.drudis.2021.09.004","volume":"27","author":"JN Hennigan","year":"2022","unstructured":"Hennigan, J. N. & Lynch, M. D. The past, present, and future of enzyme-based therapies. Drug. Discov. Today 27, 117\u2013133 (2022).","journal-title":"Drug. Discov. Today"},{"key":"1459_CR115","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3390\/pharmaceutics15010166","volume":"15","author":"T Vavilis","year":"2023","unstructured":"Vavilis, T. et al. mRNA in the context of protein replacement therapy. Pharmaceutics 15, 166 (2023).","journal-title":"Pharmaceutics"},{"key":"1459_CR116","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1016\/j.ymthe.2025.04.045","volume":"33","author":"BJ Byrne","year":"2025","unstructured":"Byrne, B. J. et al. Current clinical applications of AAV-mediated gene therapy. Mol. Ther. 33, 2479\u20132516 (2025).","journal-title":"Mol. Ther."},{"key":"1459_CR117","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ymgme.2005.07.015","volume":"86","author":"N Brunetti-Pierri","year":"2005","unstructured":"Brunetti-Pierri, N. & Lee, B. Gene therapy for inborn errors of liver metabolism. Mol. Genet. Metab. 86, 13\u201324 (2005).","journal-title":"Mol. Genet. Metab."},{"key":"1459_CR118","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1126\/science.1690918","volume":"247","author":"JA Wolff","year":"1990","unstructured":"Wolff, J. A. et al. Direct gene transfer into mouse muscle in vivo. Science 247, 1465\u20131468 (1990).","journal-title":"Science"},{"key":"1459_CR119","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1126\/science.1546298","volume":"255","author":"GF Jirikowski","year":"1992","unstructured":"Jirikowski, G. F., Sanna, P. P., Maciejewski-Lenoir, D. & Bloom, F. E. Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA. Science 255, 996\u2013998 (1992).","journal-title":"Science"},{"key":"1459_CR120","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/s41586-024-07266-7","volume":"628","author":"D Koeberl","year":"2024","unstructured":"Koeberl, D. et al. Interim analyses of a first-in-human phase 1\/2 mRNA trial for propionic acidaemia. Nature 628, 872\u2013877 (2024).","journal-title":"Nature"},{"key":"1459_CR121","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1096\/fj.08-121848","volume":"23","author":"RJ Chandler","year":"2009","unstructured":"Chandler, R. J. et al. Mitochondrial dysfunction in mut methylmalonic acidemia. FASEB J. 23, 1252\u20131261 (2009).","journal-title":"FASEB J."},{"key":"1459_CR122","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/jimd.12617","volume":"46","author":"PE Head","year":"2023","unstructured":"Head, P. E., Meier, J. L. & Venditti, C. P. New insights into the pathophysiology of methylmalonic acidemia. J. Inher Metab. Disea 46, 436\u2013449 (2023).","journal-title":"J. Inher Metab. Disea"},{"key":"1459_CR123","unstructured":"Fenton, W. A., Gravel, R. A. & Rosenblatt, D. S. Disorders of propionate and methylmalonate metabolism. In The Online Metabolic and Molecular Bases of Inherited Disease (eds Valle, D. L. et al.) Ch. 94 (McGraw-Hill Education, 2019)."},{"key":"1459_CR124","doi-asserted-by":"publisher","first-page":"6023","DOI":"10.1093\/nar\/gkx135","volume":"45","author":"YV Svitkin","year":"2017","unstructured":"Svitkin, Y. V. et al. N1-Methyl-pseudouridine in mRNA enhances translation through eIF2\u03b1-dependent and independent mechanisms by increasing ribosome density. Nucleic Acids Res. 45, 6023\u20136036 (2017).","journal-title":"Nucleic Acids Res."},{"key":"1459_CR125","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nri3247","volume":"12","author":"CJ Desmet","year":"2012","unstructured":"Desmet, C. J. & Ishii, K. J. Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat. Rev. Immunol. 12, 479\u2013491 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"1459_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2024.108560","volume":"143","author":"KA Coughlan","year":"2024","unstructured":"Coughlan, K. A. et al. Improved therapeutic efficacy in two mouse models of methylmalonic acidemia (MMA) using a second-generation mRNA therapy. Mol. Genet. Metab. 143, 108560 (2024).","journal-title":"Mol. Genet. Metab."},{"key":"1459_CR127","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1542\/pir.2018-0146","volume":"41","author":"RW Marion","year":"2020","unstructured":"Marion, R. W. & Paljevic, E. The glycogen storage disorders. Pediatr. Rev. 41, 41\u201344 (2020).","journal-title":"Pediatr. Rev."},{"key":"1459_CR128","doi-asserted-by":"publisher","first-page":"3828","DOI":"10.3390\/nu13113828","volume":"13","author":"TGJ Derks","year":"2021","unstructured":"Derks, T. G. J. et al. Glycogen storage disease type Ia: current management options, burden and unmet needs. Nutrients 13, 3828 (2021).","journal-title":"Nutrients"},{"key":"1459_CR129","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1097\/MOP.0000000000001158","volume":"34","author":"TLF Wright","year":"2022","unstructured":"Wright, T. L. F., Uma\u00f1a, L. A. & Ramirez, C. M. Update on glycogen storage disease: primary hepatic involvement. Curr. Opin. Pediatr. 34, 496\u2013502 (2022).","journal-title":"Curr. Opin. Pediatr."},{"key":"1459_CR130","doi-asserted-by":"publisher","first-page":"R31","DOI":"10.1093\/hmg\/ddz133","volume":"28","author":"PS Kishnani","year":"2019","unstructured":"Kishnani, P. S., Sun, B. & Koeberl, D. D. Gene therapy for glycogen storage diseases. Hum. Mol. Genet. 28, R31\u2013R41 (2019).","journal-title":"Hum. Mol. Genet."},{"key":"1459_CR131","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.110.RC3.6","author":"J Mitchell","year":"2025","unstructured":"Mitchell, J. et al. Efficacy and safety results from a pivotal phase 3 trial of DTX401, an AAV8-mediated liver-directed gene therapy, in individuals with glycogen storage disease type Ia (GSDIa). Endocrine Abstracts https:\/\/doi.org\/10.1530\/endoabs.110.RC3.6 (2025).","journal-title":"Endocrine Abstracts"},{"key":"1459_CR132","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.70014","volume":"48","author":"DA Weinstein","year":"2025","unstructured":"Weinstein, D. A. et al. Safety and efficacy of DTX401, an AAV8-mediated liver-directed gene therapy, in adults with glycogen storage disease type I a (GSDIa). J. Inher. Metab. Dis. 48, e70014 (2025).","journal-title":"J. Inher. Metab. Dis."},{"key":"1459_CR133","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.ymthe.2018.01.006","volume":"26","author":"DS Roseman","year":"2018","unstructured":"Roseman, D. S. et al. G6PC mRNA therapy positively regulates fasting blood glucose and decreases liver abnormalities in a mouse model of glycogen storage disease 1a. Mol. Ther. 26, 814\u2013821 (2018).","journal-title":"Mol. Ther."},{"key":"1459_CR134","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23318-2","volume":"12","author":"J Cao","year":"2021","unstructured":"Cao, J. et al. mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease. Nat. Commun. 12, 3090 (2021).","journal-title":"Nat. Commun."},{"key":"1459_CR135","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1038\/mt.2008.72","volume":"16","author":"SC Cunningham","year":"2008","unstructured":"Cunningham, S. C., Dane, A. P., Spinoulas, A. & Alexander, I. E. Gene delivery to the juvenile mouse liver using AAV2\/8 vectors. Mol. Ther. 16, 1081\u20131088 (2008).","journal-title":"Mol. Ther."},{"key":"1459_CR136","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/mt.2010.64","volume":"18","author":"WH Yiu","year":"2010","unstructured":"Yiu, W. H. et al. Complete normalization of hepatic G6PC deficiency in murine glycogen storage disease type Ia using gene therapy. Mol. Ther. 18, 1076\u20131084 (2010).","journal-title":"Mol. Ther."},{"key":"1459_CR137","doi-asserted-by":"publisher","first-page":"658399","DOI":"10.3389\/fimmu.2021.658399","volume":"12","author":"T Weber","year":"2021","unstructured":"Weber, T. Anti-AAV antibodies in AAV gene therapy: current challenges and possible solutions. Front. Immunol. 12, 658399 (2021).","journal-title":"Front. Immunol."},{"key":"1459_CR138","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54108-1","volume":"15","author":"I Arnaoutova","year":"2024","unstructured":"Arnaoutova, I. et al. Base-editing corrects metabolic abnormalities in a humanized mouse model for glycogen storage disease type-Ia. Nat. Commun. 15, 9729 (2024).","journal-title":"Nat. Commun."},{"key":"1459_CR139","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s10545-017-0054-2","volume":"40","author":"GO Okechuku","year":"2017","unstructured":"Okechuku, G. O. et al. Tight metabolic control plus ACE inhibitor therapy improves GSD I nephropathy. J. Inher. Metab. Dis. 40, 703\u2013708 (2017).","journal-title":"J. Inher. Metab. Dis."},{"key":"1459_CR140","doi-asserted-by":"crossref","unstructured":"Beegle, R. D., Brown, L. M. & Weinstein, D. A. Regression of hepatocellular adenomas with strict dietary therapy in patients with glycogen storage disease type I. In JIMD Reports, Vol. 18 (eds Zschocke, J. et al.) (Springer, 2014).","DOI":"10.1007\/8904_2014_344"},{"key":"1459_CR141","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/pedi.12540","volume":"18","author":"M Dambska","year":"2017","unstructured":"Dambska, M., Labrador, E., Kuo, C. & Weinstein, D. Prevention of complications in glycogen storage disease type Ia with optimization of metabolic control: Dambska et al. Pediatr. Diabetes 18, 327\u2013331 (2017).","journal-title":"Pediatr. Diabetes"},{"key":"1459_CR142","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3390\/nano10020364","volume":"10","author":"I G\u00f3mez-Aguado","year":"2020","unstructured":"G\u00f3mez-Aguado, I. et al. Nanomedicines to deliver mRNA: state of the art and future perspectives. Nanomaterials 10, 364 (2020).","journal-title":"Nanomaterials"},{"key":"1459_CR143","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04416126 (2023)."},{"key":"1459_CR144","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06488313 (2025)."},{"key":"1459_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2020.107534","volume":"40","author":"Y Weng","year":"2020","unstructured":"Weng, Y. et al. The challenge and prospect of mRNA therapeutics landscape. Biotechnol. Adv. 40, 107534 (2020).","journal-title":"Biotechnol. Adv."},{"key":"1459_CR146","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Q Cheng","year":"2020","unstructured":"Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing. Nat. Nanotechnol. 15, 313\u2013320 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"1459_CR147","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jconrel.2016.01.020","volume":"240","author":"Y-N Zhang","year":"2016","unstructured":"Zhang, Y.-N., Poon, W., Tavares, A. J., McGilvray, I. D. & Chan, W. C. W. Nanoparticle\u2013liver interactions: cellular uptake and hepatobiliary elimination. J. Control. Rel. 240, 332\u2013348 (2016).","journal-title":"J. Control. Rel."},{"key":"1459_CR148","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202211420","volume":"35","author":"K Lam","year":"2023","unstructured":"Lam, K. et al. Optimizing lipid nanoparticles for delivery in primates. Adv. Mater. 35, e2211420 (2023).","journal-title":"Adv. Mater."},{"key":"1459_CR149","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1038\/s41551-024-01267-7","volume":"8","author":"X Han","year":"2024","unstructured":"Han, X. et al. Optimization of the activity and biodegradability of ionizable lipids for mRNA delivery via directed chemical evolution. Nat. Biomed. Eng. 8, 1412\u20131424 (2024).","journal-title":"Nat. Biomed. Eng."},{"key":"1459_CR150","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55072-6","volume":"15","author":"W Wang","year":"2024","unstructured":"Wang, W. et al. Artificial intelligence-driven rational design of ionizable lipids for mRNA delivery. Nat. Commun. 15, 10804 (2024).","journal-title":"Nat. Commun."},{"key":"1459_CR151","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27493-0","volume":"12","author":"X Han","year":"2021","unstructured":"Han, X. et al. An ionizable lipid toolbox for RNA delivery. Nat. Commun. 12, 7233 (2021).","journal-title":"Nat. Commun."},{"key":"1459_CR152","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.addr.2020.06.017","volume":"154\u2013155","author":"R B\u00f6ttger","year":"2020","unstructured":"B\u00f6ttger, R. et al. Lipid-based nanoparticle technologies for liver targeting. Adv. Drug. Delivery Rev. 154\u2013155, 79\u2013101 (2020).","journal-title":"Adv. Drug. Delivery Rev."},{"key":"1459_CR153","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.3390\/biomedicines11061735","volume":"11","author":"O Daly","year":"2023","unstructured":"Daly, O. et al. ASL mRNA\u2013LNP therapeutic for the treatment of argininosuccinic aciduria enables survival benefit in a mouse model. Biomedicines 11, 1735 (2023).","journal-title":"Biomedicines"},{"key":"1459_CR154","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/CJI.0b013e3181a00068","volume":"32","author":"B Weide","year":"2009","unstructured":"Weide, B. et al. Direct injection of protamine-protected mRNA: results of a phase 1\/2 vaccination trial in metastatic melanoma patients. J. Immunother. 32, 498 (2009).","journal-title":"J. Immunother."},{"key":"1459_CR155","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin, U., Karik\u00f3, K. & T\u00fcreci, \u00d6 mRNA-based therapeutics\u2014developing a new class of drugs. Nat. Rev. Drug. Discov. 13, 759\u2013780 (2014).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1459_CR156","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/d41573-021-00110-x","volume":"20","author":"A Mullard","year":"2021","unstructured":"Mullard, A. COVID-19 vaccine success enables a bolder vision for mRNA cancer vaccines, says BioNTech CEO. Nat. Rev. Drug. Discov. 20, 500\u2013501 (2021).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1459_CR157","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1200\/JCO.2019.37.15_suppl.2643","volume":"37","author":"G Cafri","year":"2019","unstructured":"Cafri, G. et al. Immunogenicity and tolerability of personalized mRNA vaccine mRNA-4650 encoding defined neoantigens expressed by the autologous cancer. J. Clin. Oncol. 37, 2643\u20132643 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1459_CR158","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/d41586-024-01717-x","volume":"630","author":"E Dolgin","year":"2024","unstructured":"Dolgin, E. How personalized cancer vaccines could keep tumours from coming back. Nature 630, 290\u2013292 (2024).","journal-title":"Nature"},{"key":"1459_CR159","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222\u2013226 (2017).","journal-title":"Nature"},{"key":"1459_CR160","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403, 632\u2013644 (2024).","journal-title":"Lancet"},{"key":"1459_CR161","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 541, 321\u2013330 (2017).","journal-title":"Nature"},{"key":"1459_CR162","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1038\/s41591-022-01937-6","volume":"28","author":"CD Palmer","year":"2022","unstructured":"Palmer, C. D. et al. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nat. Med. 28, 1619\u20131629 (2022).","journal-title":"Nat. Med."},{"key":"1459_CR163","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nature14001","volume":"515","author":"M Yadav","year":"2014","unstructured":"Yadav, M. et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515, 572\u2013576 (2014).","journal-title":"Nature"},{"key":"1459_CR164","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-025-01908-7","author":"S Yang","year":"2025","unstructured":"Yang, S., Ta, Y.-N. N. & Chen, Y. Nanotechnology-enhanced immunotherapies for pancreatic ductal adenocarcinoma: challenges and opportunities. Drug. Deliv. Transl. Res. https:\/\/doi.org\/10.1007\/s13346-025-01908-7 (2025).","journal-title":"Drug. Deliv. Transl. Res."},{"key":"1459_CR165","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","volume":"639","author":"Z Sethna","year":"2025","unstructured":"Sethna, Z. et al. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Nature 639, 1042\u20131051 (2025).","journal-title":"Nature"},{"key":"1459_CR166","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-10004-2","author":"U Sahin","year":"2026","unstructured":"Sahin, U. et al. Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC. Nature https:\/\/doi.org\/10.1038\/s41586-025-10004-2 (2026).","journal-title":"Nature"},{"key":"1459_CR167","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore, J. D. et al. CRISPR\u2013Cas9 in vivo gene editing for transthyretin amyloidosis. N. Engl. J. Med. 385, 493\u2013502 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1459_CR168","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04560790 (2022)."},{"key":"1459_CR169","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.122.062132","volume":"147","author":"RG Lee","year":"2023","unstructured":"Lee, R. G. et al. Efficacy and safety of an investigational single-course CRISPR base-editing therapy targeting PCSK9 in nonhuman primate and mouse models. Circulation 147, 242\u2013253 (2023).","journal-title":"Circulation"},{"key":"1459_CR170","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","volume":"593","author":"K Musunuru","year":"2021","unstructured":"Musunuru, K. et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature 593, 429\u2013434 (2021).","journal-title":"Nature"},{"key":"1459_CR171","doi-asserted-by":"publisher","DOI":"10.1016\/j.cobme.2023.100517","volume":"29","author":"AM Kabadi","year":"2024","unstructured":"Kabadi, A. M. et al. AAV-based CRISPR\u2013Cas9 genome editing: challenges and engineering opportunities. Curr. Opin. Biomed. Eng. 29, 100517 (2024).","journal-title":"Curr. Opin. Biomed. Eng."},{"key":"1459_CR172","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","volume":"38","author":"AV Anzalone","year":"2020","unstructured":"Anzalone, A. V., Koblan, L. W. & Liu, D. R. Genome editing with CRISPR\u2013Cas nucleases, base editors, transposases and prime editors. Nat. Biotechnol. 38, 824\u2013844 (2020).","journal-title":"Nat. Biotechnol."},{"key":"1459_CR173","doi-asserted-by":"publisher","first-page":"578","DOI":"10.3390\/ijms26020578","volume":"26","author":"N Bara-Ledesma","year":"2025","unstructured":"Bara-Ledesma, N. et al. Advances in gene therapy for rare diseases: targeting functional haploinsufficiency through AAV and mRNA approaches. Int. J. Mol. Sci. 26, 578 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"1459_CR174","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","volume":"8","author":"P Colella","year":"2018","unstructured":"Colella, P., Ronzitti, G. & Mingozzi, F. Emerging issues in AAV-mediated in vivo gene therapy. Mol. Ther. Methods Clin. Dev. 8, 87\u2013104 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1459_CR175","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41551-020-00671-z","volume":"5","author":"L Villiger","year":"2021","unstructured":"Villiger, L. et al. In vivo cytidine base editing of hepatocytes without detectable off-target mutations in RNA and DNA. Nat. Biomed. Eng. 5, 179\u2013189 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"1459_CR176","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.115026","volume":"200","author":"J Popovitz","year":"2023","unstructured":"Popovitz, J. et al. Gene editing therapeutics based on mRNA delivery. Adv. Drug. Delivery Rev. 200, 115026 (2023).","journal-title":"Adv. Drug. Delivery Rev."},{"key":"1459_CR177","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3390\/biomedicines9070793","volume":"9","author":"SS Sundararaman","year":"2021","unstructured":"Sundararaman, S. S., D\u00f6ring, Y. & van der Vorst, E. P. C. PCSK9: a multi-faceted protein that is involved in cardiovascular biology. Biomedicines 9, 793 (2021).","journal-title":"Biomedicines"},{"key":"1459_CR178","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-15543-x","volume":"7","author":"MD Di Taranto","year":"2017","unstructured":"Di Taranto, M. D. et al. Identification and in vitro characterization of two new PCSK9 gain of function variants found in patients with familial hypercholesterolemia. Sci. Rep. 7, 15282 (2017).","journal-title":"Sci. Rep."},{"key":"1459_CR179","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1194\/jlr.M078360","volume":"59","author":"H Sun","year":"2018","unstructured":"Sun, H., Krauss, R. M., Chang, J. T. & Teng, B.-B. PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction. J. Lipid Res. 59, 207\u2013223 (2018).","journal-title":"J. Lipid Res."},{"key":"1459_CR180","doi-asserted-by":"publisher","first-page":"595819","DOI":"10.3389\/fphys.2020.595819","volume":"11","author":"JL Katzmann","year":"2020","unstructured":"Katzmann, J. L., Gouni-Berthold, I. & Laufs, U. PCSK9 inhibition: insights from clinical trials and future prospects. Front. Physiol. 11, 595819 (2020).","journal-title":"Front. Physiol."},{"key":"1459_CR181","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37465-1","volume":"14","author":"LN Kasiewicz","year":"2023","unstructured":"Kasiewicz, L. N. et al. GalNAc\u2013lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy. Nat. Commun. 14, 2776 (2023).","journal-title":"Nat. Commun."},{"key":"1459_CR182","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04254-4","author":"P Wan","year":"2026","unstructured":"Wan, P. et al. In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-026-04254-4 (2026).","journal-title":"Nat. Med."},{"key":"1459_CR183","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1609243","volume":"376","author":"K Fitzgerald","year":"2017","unstructured":"Fitzgerald, K. et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N. Engl. J. Med. 376, 41\u201351 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1459_CR184","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2504747","author":"K Musunuru","year":"2025","unstructured":"Musunuru, K. et al. Patient-specific in vivo gene editing to treat a rare genetic disease. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2504747 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1459_CR185","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2505704","author":"P Marks","year":"2025","unstructured":"Marks, P. Progress in the development of N-of-1 therapy. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMe2505704 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1459_CR186","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2505721","author":"AL Gropman","year":"2025","unstructured":"Gropman, A. L. & Komor, A. C. Personalized gene editing to treat an inborn error of metabolism. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMe2505721 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1459_CR187","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ymgme.2013.07.008","volume":"110","author":"ML Summar","year":"2013","unstructured":"Summar, M. L. et al. The incidence of urea cycle disorders. Mol. Genet. Metab. 110, 179\u2013180 (2013).","journal-title":"Mol. Genet. Metab."},{"key":"1459_CR188","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1002\/ajmg.a.62199","volume":"185","author":"J Kido","year":"2021","unstructured":"Kido, J., Matsumoto, S., Sugawara, K., Sawada, T. & Nakamura, K. Variants associated with urea cycle disorders in Japanese patients: nationwide study and literature review. Am. J. Med. Genet. Pt A 185, 2026\u20132036 (2021).","journal-title":"Am. J. Med. Genet. Pt A"},{"key":"1459_CR189","doi-asserted-by":"publisher","first-page":"4838","DOI":"10.1182\/blood-2024-203546","volume":"144","author":"C Diorio","year":"2024","unstructured":"Diorio, C. et al. BEAM-201 for the treatment of relapsed and\/or refractory (R\/R) T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LL): initial data from the phase (Ph) 1\/2 dose-exploration, dose-expansion, safety, and efficacy study of multiplex base-edited allogeneic anti-CD7 CAR-T-cells. Blood 144, 4838 (2024).","journal-title":"Blood"},{"key":"1459_CR190","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41576-022-00541-1","volume":"24","author":"PJ Chen","year":"2023","unstructured":"Chen, P. J. & Liu, D. R. Prime editing for precise and highly versatile genome manipulation. Nat. Rev. Genet. 24, 161\u2013177 (2023).","journal-title":"Nat. Rev. Genet."},{"key":"1459_CR191","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33157-4","volume":"13","author":"S Li","year":"2022","unstructured":"Li, S. et al. Payload distribution and capacity of mRNA lipid nanoparticles. Nat. Commun. 13, 5561 (2022).","journal-title":"Nat. Commun."},{"key":"1459_CR192","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02137-y","author":"X Zhang","year":"2024","unstructured":"Zhang, X. et al. Harnessing eukaryotic retroelement proteins for transgene insertion into human safe-harbor loci. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-024-02137-y (2024).","journal-title":"Nat. Biotechnol."},{"key":"1459_CR193","doi-asserted-by":"publisher","first-page":"4674","DOI":"10.1016\/j.cell.2024.06.020","volume":"187","author":"Y Chen","year":"2024","unstructured":"Chen, Y. et al. All-RNA-mediated targeted gene integration in mammalian cells with rationally engineered R2 retrotransposons. Cell 187, 4674\u20134689.e18 (2024).","journal-title":"Cell"},{"key":"1459_CR194","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s41587-022-01527-4","volume":"41","author":"MTN Yarnall","year":"2023","unstructured":"Yarnall, M. T. N. et al. Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases. Nat. Biotechnol. 41, 500\u2013512 (2023).","journal-title":"Nat. Biotechnol."},{"key":"1459_CR195","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1126\/science.ade6967","volume":"381","author":"L Breda","year":"2023","unstructured":"Breda, L. et al. In vivo hematopoietic stem cell modification by mRNA delivery. Science 381, 436\u2013443 (2023).","journal-title":"Science"},{"key":"1459_CR196","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2031054","volume":"384","author":"H Frangoul","year":"2021","unstructured":"Frangoul, H. et al. CRISPR\u2013Cas9 gene editing for sickle cell disease and \u03b2-thalassemia. N. Engl. J. Med. 384, 252\u2013260 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1459_CR197","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1182\/blood-2022-165089","volume":"140","author":"L Breda","year":"2022","unstructured":"Breda, L. et al. In vivo modification of hematopoietic stem cells by targeted lipid nanoparticles encapsulating mRNA. Blood 140, 305\u2013306 (2022).","journal-title":"Blood"},{"key":"1459_CR198","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1021\/acs.nanolett.3c00304","volume":"23","author":"D Shi","year":"2023","unstructured":"Shi, D., Toyonaga, S. & Anderson, D. G. In vivo RNA delivery to hematopoietic stem and progenitor cells via targeted lipid nanoparticles. Nano Lett. 23, 2938\u20132944 (2023).","journal-title":"Nano Lett."},{"key":"1459_CR199","unstructured":"Masson, G. Vertex pays Orna $65M to work on next-gen gene therapies for blood disorders. Fierce Biotech https:\/\/www.fiercebiotech.com\/biotech\/vertex-pays-orna-65m-work-next-gen-gene-therapies-blood-disorders (7 January 2025)."},{"key":"1459_CR200","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/s41565-024-01680-8","volume":"19","author":"X Lian","year":"2024","unstructured":"Lian, X. et al. Bone-marrow-homing lipid nanoparticles for genome editing in diseased and malignant haematopoietic stem cells. Nat. Nanotechnol. 19, 1409\u20131417 (2024).","journal-title":"Nat. Nanotechnol."},{"key":"1459_CR201","doi-asserted-by":"publisher","first-page":"9926","DOI":"10.1021\/jacs.2c02706","volume":"144","author":"L Xue","year":"2022","unstructured":"Xue, L. et al. Rational design of bisphosphonate lipid-like materials for mRNA delivery to the bone microenvironment. J. Am. Chem. Soc. 144, 9926\u20139937 (2022).","journal-title":"J. Am. Chem. Soc."},{"key":"1459_CR202","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-024-01847-3","author":"SRJ Hofstraat","year":"2025","unstructured":"Hofstraat, S. R. J. et al. Nature-inspired platform nanotechnology for RNA delivery to myeloid cells and their bone marrow progenitors. Nat. Nanotechnol. https:\/\/doi.org\/10.1038\/s41565-024-01847-3 (2025).","journal-title":"Nat. Nanotechnol."},{"key":"1459_CR203","doi-asserted-by":"publisher","unstructured":"Amabile, A. et al. Bispecific antibody targeting of lipid nanoparticles. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2024.12.20.629467 (2024).","DOI":"10.1101\/2024.12.20.629467"},{"key":"1459_CR204","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add4623","volume":"9","author":"M Herrera-Barrera","year":"2023","unstructured":"Herrera-Barrera, M. et al. Peptide-guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates. Sci. Adv. 9, eadd4623 (2023).","journal-title":"Sci. Adv."},{"key":"1459_CR205","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1021\/acs.nanolett.4c05186","volume":"25","author":"EL Han","year":"2025","unstructured":"Han, E. L. et al. Peptide-functionalized lipid nanoparticles for targeted systemic mRNA delivery to the brain. Nano Lett. 25, 800\u2013810 (2025).","journal-title":"Nano Lett."},{"key":"1459_CR206","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/mt.2010.85","volume":"18","author":"A Akinc","year":"2010","unstructured":"Akinc, A. et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 18, 1357\u20131364 (2010).","journal-title":"Mol. Ther."},{"key":"1459_CR207","doi-asserted-by":"publisher","first-page":"5216","DOI":"10.1016\/j.bmc.2008.03.017","volume":"16","author":"O Khorev","year":"2008","unstructured":"Khorev, O., Stokmaier, D., Schwardt, O., Cutting, B. & Ernst, B. Trivalent, Gal\/GalNAc-containing ligands designed for the asialoglycoprotein receptor. Bioorg. Med. Chem. 16, 5216\u20135231 (2008).","journal-title":"Bioorg. Med. Chem."},{"key":"1459_CR208","doi-asserted-by":"publisher","first-page":"12388","DOI":"10.1093\/nar\/gkx960","volume":"45","author":"M Tanowitz","year":"2017","unstructured":"Tanowitz, M. et al. Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes. Nucleic Acids Res. 45, 12388\u201312400 (2017).","journal-title":"Nucleic Acids Res."},{"key":"1459_CR209","doi-asserted-by":"publisher","first-page":"16958","DOI":"10.1021\/ja505986a","volume":"136","author":"JK Nair","year":"2014","unstructured":"Nair, J. K. et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am. Chem. Soc. 136, 16958\u201316961 (2014).","journal-title":"J. Am. Chem. Soc."},{"key":"1459_CR210","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ade1444","volume":"9","author":"JR Melamed","year":"2023","unstructured":"Melamed, J. R. et al. Ionizable lipid nanoparticles deliver mRNA to pancreatic \u03b2 cells via macrophage-mediated gene transfer. Sci. Adv. 9, eade1444 (2023).","journal-title":"Sci. Adv."},{"key":"1459_CR211","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2207841119","volume":"119","author":"J Chen","year":"2022","unstructured":"Chen, J. et al. Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8+ T cell response. Proc. Natl Acad. Sci. USA 119, e2207841119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1459_CR212","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.addr.2020.06.003","volume":"167","author":"T Nakamura","year":"2020","unstructured":"Nakamura, T. & Harashima, H. Dawn of lipid nanoparticles in lymph node targeting: potential in cancer immunotherapy. Adv. Drug. Delivery Rev. 167, 78\u201388 (2020).","journal-title":"Adv. Drug. Delivery Rev."},{"key":"1459_CR213","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/s41375-020-0951-5","volume":"35","author":"L Lin","year":"2021","unstructured":"Lin, L. et al. Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma. Leukemia 35, 752\u2013763 (2021).","journal-title":"Leukemia"},{"key":"1459_CR214","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","volume":"22","author":"V Granit","year":"2023","unstructured":"Granit, V. et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study. Lancet Neurol. 22, 578\u2013590 (2023).","journal-title":"Lancet Neurol."},{"key":"1459_CR215","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/s41591-025-04171-y","volume":"32","author":"T Vu","year":"2026","unstructured":"Vu, T. et al. BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial. Nat. Med. 32, 1131\u20131141 (2026).","journal-title":"Nat. Med."},{"key":"1459_CR216","doi-asserted-by":"publisher","first-page":"4747","DOI":"10.1158\/1078-0432.CCR-21-4384","volume":"28","author":"H Meister","year":"2022","unstructured":"Meister, H. et al. Multifunctional mRNA-based CAR T cells display promising antitumor activity against glioblastoma. Clin. Cancer Res. 28, 4747\u20134756 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1459_CR217","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","volume":"29","author":"A Mackensen","year":"2023","unstructured":"Mackensen, A. et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat. Med. 29, 2844\u20132853 (2023).","journal-title":"Nat. Med."},{"key":"1459_CR218","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004450","volume":"10","author":"JB Foster","year":"2022","unstructured":"Foster, J. B. et al. Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors. J. Immunother. Cancer 10, e004450 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1459_CR219","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","volume":"619","author":"DJ Baker","year":"2023","unstructured":"Baker, D. J., Arany, Z., Baur, J. A., Epstein, J. A. & June, C. H. CAR T therapy beyond cancer: the evolution of a living drug. Nature 619, 707\u2013715 (2023).","journal-title":"Nature"},{"key":"1459_CR220","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik, J. G. et al. CAR T cells produced in vivo to treat cardiac injury. Science 375, 91\u201396 (2022).","journal-title":"Science"},{"key":"1459_CR221","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1021\/acs.nanolett.1c02503","volume":"22","author":"MM Billingsley","year":"2022","unstructured":"Billingsley, M. M. et al. Orthogonal design of experiments for optimization of lipid nanoparticles for mRNA engineering of CAR T cells. Nano Lett. 22, 533\u2013542 (2022).","journal-title":"Nano Lett."},{"key":"1459_CR222","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1016\/j.ymthe.2021.06.004","volume":"29","author":"I Tomb\u00e1cz","year":"2021","unstructured":"Tomb\u00e1cz, I. et al. Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA\u2013LNPs. Mol. Ther. 29, 3293\u20133304 (2021).","journal-title":"Mol. Ther."},{"key":"1459_CR223","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202304378","volume":"20","author":"MM Billingsley","year":"2024","unstructured":"Billingsley, M. M. et al. In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism. Small 20, 2304378 (2024).","journal-title":"Small"},{"key":"1459_CR224","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1126\/science.ads8473","volume":"388","author":"TL Hunter","year":"2025","unstructured":"Hunter, T. L. et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science 388, 1311\u20131317 (2025).","journal-title":"Science"},{"key":"1459_CR225","first-page":"486","volume":"38","author":"S-H Bae","year":"2024","unstructured":"Bae, S.-H. et al. A lipid nanoparticle platform incorporating trehalose glycolipid for exceptional mRNA vaccine safety. Bioact. Mater. 38, 486\u2013498 (2024).","journal-title":"Bioact. Mater."},{"key":"1459_CR226","doi-asserted-by":"publisher","first-page":"10634","DOI":"10.1021\/acsanm.0c01834","volume":"3","author":"SS Nogueira","year":"2020","unstructured":"Nogueira, S. S. et al. Polysarcosine-functionalized lipid nanoparticles for therapeutic mRNA delivery. ACS Appl. Nano Mater. 3, 10634\u201310645 (2020).","journal-title":"ACS Appl. Nano Mater."},{"key":"1459_CR227","first-page":"86","volume":"37","author":"DD Kang","year":"2024","unstructured":"Kang, D. D. et al. Engineering LNPs with polysarcosine lipids for mRNA delivery. Bioact. Mater. 37, 86\u201393 (2024).","journal-title":"Bioact. Mater."},{"key":"1459_CR228","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1021\/acs.bioconjchem.3c00174","volume":"34","author":"R Tenchov","year":"2023","unstructured":"Tenchov, R., Sasso, J. M. & Zhou, Q. A. PEGylated lipid nanoparticle formulations: immunological safety and efficiency perspective. Bioconjugate Chem. 34, 941\u2013960 (2023).","journal-title":"Bioconjugate Chem."},{"key":"1459_CR229","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1038\/s41565-021-01001-3","volume":"16","author":"P Bigini","year":"2021","unstructured":"Bigini, P. et al. The role and impact of polyethylene glycol on anaphylactic reactions to COVID-19 nano-vaccines. Nat. Nanotechnol. 16, 1169\u20131171 (2021).","journal-title":"Nat. Nanotechnol."},{"key":"1459_CR230","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","volume":"15","author":"M Baiersd\u00f6rfer","year":"2019","unstructured":"Baiersd\u00f6rfer, M. et al. A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA. Mol. Ther. Nucleic Acids 15, 26\u201335 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1459_CR231","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.omtn.2022.08.001","volume":"29","author":"X Piao","year":"2022","unstructured":"Piao, X. et al. Double-stranded RNA reduction by chaotropic agents during in vitro transcription of messenger RNA. Mol. Ther. Nucleic Acids 29, 618\u2013624 (2022).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1459_CR232","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41587-022-01525-6","volume":"41","author":"A Dousis","year":"2023","unstructured":"Dousis, A., Ravichandran, K., Hobert, E. M., Moore, M. J. & Rabideau, A. E. An engineered T7 RNA polymerase that produces mRNA free of immunostimulatory byproducts. Nat. Biotechnol. 41, 560\u2013568 (2023).","journal-title":"Nat. Biotechnol."},{"key":"1459_CR233","doi-asserted-by":"publisher","first-page":"1248511","DOI":"10.3389\/fmolb.2023.1248511","volume":"10","author":"J Mart\u00ednez","year":"2023","unstructured":"Mart\u00ednez, J., Lampaya, V., Larraga, A., Magall\u00f3n, H. & Casabona, D. Purification of linearized template plasmid DNA decreases double-stranded RNA formation during IVT reaction. Front. Mol. Biosci. 10, 1248511 (2023).","journal-title":"Front. Mol. Biosci."},{"key":"1459_CR234","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1126\/science.aay3638","volume":"371","author":"C Krienke","year":"2021","unstructured":"Krienke, C. et al. A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science 371, 145\u2013153 (2021).","journal-title":"Science"},{"key":"1459_CR235","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2021.101370","volume":"42","author":"Q Liu","year":"2022","unstructured":"Liu, Q. et al. Use of a liver-targeting nanoparticle platform to intervene in peanut-induced anaphylaxis through delivery of an Ara h2 T-cell epitope. Nano Today 42, 101370 (2022).","journal-title":"Nano Today"},{"key":"1459_CR236","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1515\/mr-2023-0008","volume":"3","author":"W Cao","year":"2021","unstructured":"Cao, W. & Xia, T. mRNA lipid nanoparticles induce immune tolerance to treat human diseases. Med. Rev. 3, 180\u2013183 (2021).","journal-title":"Med. Rev."},{"key":"1459_CR237","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.omtn.2018.06.010","volume":"12","author":"S Vaidyanathan","year":"2018","unstructured":"Vaidyanathan, S. et al. Uridine depletion and chemical modification increase Cas9 mRNA activity and reduce immunogenicity without HPLC purification. Mol. Ther. Nucleic Acids 12, 530\u2013542 (2018).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1459_CR238","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.cell.2015.02.029","volume":"160","author":"V Presnyak","year":"2015","unstructured":"Presnyak, V. et al. Codon optimality is a major determinant of mRNA stability. Cell 160, 1111\u20131124 (2015).","journal-title":"Cell"},{"key":"1459_CR239","doi-asserted-by":"publisher","first-page":"D231","DOI":"10.1093\/nar\/gkab1083","volume":"50","author":"P Boccaletto","year":"2022","unstructured":"Boccaletto, P. et al. MODOMICS: a database of RNA modification pathways. 2021 update. Nucleic Acids Res. 50, D231\u2013D235 (2022).","journal-title":"Nucleic Acids Res."},{"key":"1459_CR240","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz6893","volume":"6","author":"J Nelson","year":"2020","unstructured":"Nelson, J. et al. Impact of mRNA chemistry and manufacturing process on innate immune activation. Sci. Adv. 6, eaaz6893 (2020).","journal-title":"Sci. Adv."},{"key":"1459_CR241","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jconrel.2023.03.039","volume":"357","author":"S Meulewaeter","year":"2023","unstructured":"Meulewaeter, S. et al. Continuous freeze-drying of messenger RNA lipid nanoparticles enables storage at higher temperatures. J. Control. Rel. 357, 149\u2013160 (2023).","journal-title":"J. Control. Rel."},{"key":"1459_CR242","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jconrel.2022.08.009","volume":"350","author":"B Bogaert","year":"2022","unstructured":"Bogaert, B. et al. A lipid nanoparticle platform for mRNA delivery through repurposing of cationic amphiphilic drugs. J. Control. Rel. 350, 256\u2013270 (2022).","journal-title":"J. Control. Rel."},{"key":"1459_CR243","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jconrel.2022.11.037","volume":"353","author":"AJ Da Silva Sanchez","year":"2023","unstructured":"Da Silva Sanchez, A. J. et al. Substituting racemic ionizable lipids with stereopure ionizable lipids can increase mRNA delivery. J. Control. Rel. 353, 270\u2013277 (2023).","journal-title":"J. Control. Rel."},{"key":"1459_CR244","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43065-w","volume":"14","author":"H Ning","year":"2023","unstructured":"Ning, H. et al. Rational design of microRNA-responsive switch for programmable translational control in mammalian cells. Nat. Commun. 14, 7193 (2023).","journal-title":"Nat. Commun."},{"key":"1459_CR245","doi-asserted-by":"publisher","first-page":"102609","DOI":"10.1016\/j.omtn.2025.102609","volume":"36","author":"K Masaki","year":"2025","unstructured":"Masaki, K., Fujita, Y. & Saito, H. microRNA-responsive ON\u2013OFF hybrid mRNA switch for precise protein expression control. Mol. Ther. Nucleic Acids 36, 102609 (2025).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1459_CR246","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60392-2","volume":"16","author":"I Abe","year":"2025","unstructured":"Abe, I., Ohno, H., Mochizuki, M., Hayashi, K. & Saito, H. Split RNA switch orchestrates pre- and post-translational control to enable cell type-specific gene expression. Nat. Commun. 16, 5362 (2025).","journal-title":"Nat. Commun."},{"key":"1459_CR247","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adu1493","volume":"17","author":"X Huang","year":"2025","unstructured":"Huang, X. et al. Oral delivery of liquid mRNA therapeutics by an engineered capsule for treatment of preclinical intestinal disease. Sci. Transl. Med. 17, eadu1493 (2025).","journal-title":"Sci. Transl. Med."},{"key":"1459_CR248","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1038\/s44319-024-00216-4","volume":"25","author":"A Macht","year":"2024","unstructured":"Macht, A. et al. Mucosal IFN\u03bb1 mRNA-based immunomodulation effectively reduces SARS-CoV-2 induced mortality in mice. EMBO Rep. 25, 3777\u20133788 (2024).","journal-title":"EMBO Rep."},{"key":"1459_CR249","doi-asserted-by":"publisher","first-page":"6584","DOI":"10.1021\/acs.nanolett.1c01973","volume":"21","author":"AJ Sinegra","year":"2021","unstructured":"Sinegra, A. J., Evangelopoulos, M., Park, J., Huang, Z. & Mirkin, C. A. Lipid nanoparticle spherical nucleic acids for intracellular DNA and RNA delivery. Nano Lett. 21, 6584\u20136591 (2021).","journal-title":"Nano Lett."},{"key":"1459_CR250","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3390\/pharmaceutics14020398","volume":"14","author":"SC Semple","year":"2022","unstructured":"Semple, S. C., Leone, R., Barbosa, C. J., Tam, Y. K. & Lin, P. J. C. Lipid nanoparticle delivery systems to enable mRNA-based therapeutics. Pharmaceutics 14, 398 (2022).","journal-title":"Pharmaceutics"},{"key":"1459_CR251","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jconrel.2022.03.046","volume":"345","author":"ST LoPresti","year":"2022","unstructured":"LoPresti, S. T., Arral, M. L., Chaudhary, N. & Whitehead, K. A. The replacement of helper lipids with charged alternatives in lipid nanoparticles facilitates targeted mRNA delivery to the spleen and lungs. J. Control. Rel. 345, 819\u2013831 (2022).","journal-title":"J. Control. Rel."},{"key":"1459_CR252","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1073\/pnas.1620874114","volume":"114","author":"JE Dahlman","year":"2017","unstructured":"Dahlman, J. E. et al. Barcoded nanoparticles for high throughput in vivo discovery of targeted therapeutics. Proc. Natl Acad. Sci. USA 114, 2060\u20132065 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1459_CR253","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1038\/s41587-024-02470-2","volume":"43","author":"H Kim","year":"2025","unstructured":"Kim, H. et al. Lipid nanoparticle-mediated mRNA delivery to CD34+ cells in rhesus monkeys. Nat. Biotechnol. 43, 1813\u20131820 (2025).","journal-title":"Nat. Biotechnol."},{"key":"1459_CR254","doi-asserted-by":"publisher","first-page":"13790","DOI":"10.1021\/acsnano.4c16617","volume":"19","author":"RM Haley","year":"2025","unstructured":"Haley, R. M. et al. Lipid nanoparticles for in vivo lung delivery of CRISPR\u2013Cas9 ribonucleoproteins allow gene editing of clinical targets. ACS Nano 19, 13790\u201313804 (2025).","journal-title":"ACS Nano"},{"key":"1459_CR255","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/s41586-024-07087-8","volume":"627","author":"MA Cappelluti","year":"2024","unstructured":"Cappelluti, M. A. et al. Durable and efficient gene silencing in vivo by hit-and-run epigenome editing. Nature 627, 416\u2013423 (2024).","journal-title":"Nature"},{"key":"1459_CR256","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2421915122","volume":"122","author":"M Hennig","year":"2025","unstructured":"Hennig, M. et al. Inhaled DNAI1 mRNA therapy for treatment of primary ciliary dyskinesia. Proc. Natl Acad. Sci. USA 122, e2421915122 (2025).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1459_CR257","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1056\/NEJMoa2405734","volume":"392","author":"DM Cohn","year":"2025","unstructured":"Cohn, D. M. et al. CRISPR-based therapy for hereditary angioedema. N. Engl. J. Med. 392, 458\u2013467 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1459_CR258","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41587-022-01393-0","volume":"41","author":"R Chen","year":"2023","unstructured":"Chen, R. et al. Engineering circular RNA for enhanced protein production. Nat. Biotechnol. 41, 262\u2013272 (2023).","journal-title":"Nat. Biotechnol."},{"key":"1459_CR259","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17409-9","volume":"11","author":"PF McKay","year":"2020","unstructured":"McKay, P. F. et al. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. Nat. Commun. 11, 3523 (2020).","journal-title":"Nat. Commun."},{"key":"1459_CR260","doi-asserted-by":"publisher","first-page":"101262","DOI":"10.1016\/j.eclinm.2021.101262","volume":"44","author":"KM Pollock","year":"2022","unstructured":"Pollock, K. M. et al. Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial. eClinicalMedicine 44, 101262 (2022).","journal-title":"eClinicalMedicine"},{"key":"1459_CR261","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1261\/rna.069286.118","volume":"25","author":"Z Trepotec","year":"2019","unstructured":"Trepotec, Z., Geiger, J., Plank, C., Aneja, M. K. & Rudolph, C. Segmented poly(A) tails significantly reduce recombination of plasmid DNA without affecting mRNA translation efficiency or half-life. RNA 25, 507\u2013518 (2019).","journal-title":"RNA"},{"key":"1459_CR262","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","volume":"26","author":"AB Vogel","year":"2018","unstructured":"Vogel, A. B. et al. Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses. Mol. Ther. 26, 446\u2013455 (2018).","journal-title":"Mol. Ther."},{"key":"1459_CR263","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05096-6","volume":"9","author":"RA Wesselhoeft","year":"2018","unstructured":"Wesselhoeft, R. A., Kowalski, P. S. & Anderson, D. G. Engineering circular RNA for potent and stable translation in eukaryotic cells. Nat. Commun. 9, 2629 (2018).","journal-title":"Nat. Commun."},{"key":"1459_CR264","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06714253 (2026)."},{"key":"1459_CR265","doi-asserted-by":"publisher","first-page":"12884","DOI":"10.3390\/ijms232112884","volume":"23","author":"D Papukashvili","year":"2022","unstructured":"Papukashvili, D. et al. Self-amplifying RNA approach for protein replacement therapy. IJMS 23, 12884 (2022).","journal-title":"IJMS"},{"key":"1459_CR266","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.coviro.2020.08.003","volume":"44","author":"MC Ballesteros-Briones","year":"2020","unstructured":"Ballesteros-Briones, M. C., Silva-Pilipich, N., Herrador-Ca\u00f1ete, G., Vanrell, L. & Smerdou, C. A new generation of vaccines based on alphavirus self-amplifying RNA. Curr. Opin. Virol. 44, 145\u2013153 (2020).","journal-title":"Curr. Opin. Virol."},{"key":"1459_CR267","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.addr.2020.12.014","volume":"170","author":"J Kim","year":"2021","unstructured":"Kim, J., Eygeris, Y., Gupta, M. & Sahay, G. Self-assembled mRNA vaccines. Adv. Drug. Delivery Rev. 170, 83\u2013112 (2021).","journal-title":"Adv. Drug. Delivery Rev."},{"key":"1459_CR268","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ymthe.2019.01.020","volume":"27","author":"G Maruggi","year":"2019","unstructured":"Maruggi, G., Zhang, C., Li, J., Ulmer, J. B. & Yu, D. mRNA as a transformative technology for vaccine development to control infectious diseases. Mol. Ther. 27, 757\u2013772 (2019).","journal-title":"Mol. Ther."},{"key":"1459_CR269","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41434-020-00204-y","volume":"28","author":"K Bloom","year":"2021","unstructured":"Bloom, K., van den Berg, F. & Arbuthnot, P. Self-amplifying RNA vaccines for infectious diseases. Gene Ther. 28, 117\u2013129 (2021).","journal-title":"Gene Ther."},{"key":"1459_CR270","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.4049\/jimmunol.1601877","volume":"198","author":"T Pepini","year":"2017","unstructured":"Pepini, T. et al. Induction of an IFN-mediated antiviral response by a self-amplifying RNA vaccine: implications for vaccine design. J. Immunol. 198, 4012\u20134024 (2017).","journal-title":"J. Immunol."},{"key":"1459_CR271","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2025.102453","volume":"36","author":"B Torkzaban","year":"2025","unstructured":"Torkzaban, B. et al. Use of polyadenosine tail mimetics to enhance mRNA expression from genes associated with haploinsufficiency disorders. Mol. Ther. Nucleic Acids 36, 102453 (2025).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1459_CR272","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/s41587-024-02393-y","volume":"43","author":"H Chen","year":"2025","unstructured":"Chen, H. et al. Chemical and topological design of multicapped mRNA and capped circular RNA to augment translation. Nat. Biotechnol. 43, 1128\u20131143 (2025).","journal-title":"Nat. Biotechnol."},{"key":"1459_CR273","doi-asserted-by":"publisher","first-page":"108015","DOI":"10.1016\/j.jbc.2024.108015","volume":"301","author":"L Jin","year":"2025","unstructured":"Jin, L., Zhou, Y., Zhang, S. & Chen, S.-J. mRNA vaccine sequence and structure design and optimization: advances and challenges. J. Biol. Chem. 301, 108015 (2025).","journal-title":"J. Biol. Chem."},{"key":"1459_CR274","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-74091-z","volume":"10","author":"H Fu","year":"2020","unstructured":"Fu, H. et al. Codon optimization with deep learning to enhance protein expression. Sci. Rep. 10, 17617 (2020).","journal-title":"Sci. Rep."},{"key":"1459_CR275","doi-asserted-by":"publisher","unstructured":"Constant, D. A. et al. Deep learning-based codon optimization with large-scale synonymous variant datasets enables generalized tunable protein expression. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2023.02.11.528149 (2023).","DOI":"10.1101\/2023.02.11.528149"},{"key":"1459_CR276","doi-asserted-by":"publisher","DOI":"10.1126\/science.adr8470","volume":"390","author":"H Zhang","year":"2025","unstructured":"Zhang, H. et al. Deep generative models design mRNA sequences with enhanced translational capacity and stability. Science 390, eadr8470 (2025).","journal-title":"Science"},{"key":"1459_CR277","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41589-025-02074-0","volume":"22","author":"Z Liu","year":"2026","unstructured":"Liu, Z. & Dong, Y. AI-powered design accelerates the development of mRNA therapeutics. Nat. Chem. Biol. 22, 15\u201316 (2026).","journal-title":"Nat. Chem. Biol."},{"key":"1459_CR278","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49508-2","volume":"15","author":"S Castillo-Hair","year":"2024","unstructured":"Castillo-Hair, S. et al. Optimizing 5\u2032UTRs for mRNA-delivered gene editing using deep learning. Nat. Commun. 15, 5284 (2024).","journal-title":"Nat. Commun."},{"key":"1459_CR279","doi-asserted-by":"publisher","unstructured":"Liu, Y., Gao, J., Zhang, X. & Fang, X. Joint Design of 5\u2032 Untranslated Region and Coding Sequence of mRNA. Preprint at arXiv https:\/\/doi.org\/10.48550\/arXiv.2410.20781 (2024).","DOI":"10.48550\/arXiv.2410.20781"},{"key":"1459_CR280","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1016\/j.csbj.2024.07.020","volume":"23","author":"D Luna-Cerralbo","year":"2024","unstructured":"Luna-Cerralbo, D. et al. A statistical-physics approach for codon usage optimisation. Comput. Struct. Biotechnol. J. 23, 3050\u20133064 (2024).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"1459_CR281","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/s41587-022-01618-2","volume":"41","author":"A Madani","year":"2023","unstructured":"Madani, A. et al. Large language models generate functional protein sequences across diverse families. Nat. Biotechnol. 41, 1099\u20131106 (2023).","journal-title":"Nat. Biotechnol."},{"key":"1459_CR282","doi-asserted-by":"publisher","first-page":"10604","DOI":"10.1093\/nar\/gkab764","volume":"49","author":"HK Wayment-Steele","year":"2021","unstructured":"Wayment-Steele, H. K. et al. Theoretical basis for stabilizing messenger RNA through secondary structure design. Nucleic Acids Res. 49, 10604\u201310617 (2021).","journal-title":"Nucleic Acids Res."},{"key":"1459_CR283","doi-asserted-by":"publisher","DOI":"10.1093\/nargab\/lqae028","volume":"6","author":"N Vostrosablin","year":"2024","unstructured":"Vostrosablin, N. et al. mRNAid, an open-source platform for therapeutic mRNA design and optimization strategies. NAR Genom. Bioinform. 6, lqae028 (2024).","journal-title":"NAR Genom. Bioinform."},{"key":"1459_CR284","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2022.167877","volume":"434","author":"W-JC Lai","year":"2022","unstructured":"Lai, W.-J. C. et al. Intrinsically unstructured sequences in the mRNA 3\u2032 UTR reduce the ability of poly(A) tail to enhance translation. J. Mol. Biol. 434, 167877 (2022).","journal-title":"J. Mol. Biol."},{"key":"1459_CR285","doi-asserted-by":"publisher","DOI":"10.1186\/s12915-024-02032-7","volume":"22","author":"N Haberman","year":"2024","unstructured":"Haberman, N. et al. Widespread 3\u2032UTR capped RNAs derive from G-rich regions in proximity to AGO2 binding sites. BMC Biol. 22, 254 (2024).","journal-title":"BMC Biol."},{"key":"1459_CR286","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49523-3","volume":"15","author":"S Carbonell-Sala","year":"2024","unstructured":"Carbonell-Sala, S. et al. CapTrap-seq: a platform-agnostic and quantitative approach for high-fidelity full-length RNA sequencing. Nat. Commun. 15, 5278 (2024).","journal-title":"Nat. Commun."},{"key":"1459_CR287","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50619-z","volume":"15","author":"Y Xu","year":"2024","unstructured":"Xu, Y. et al. AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery. Nat. Commun. 15, 6305 (2024).","journal-title":"Nat. Commun."}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01459-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01459-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01459-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:06:06Z","timestamp":1790683566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01459-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":287,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1459"],"URL":"https:\/\/doi.org\/10.1038\/s41573-026-01459-7","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"29 April 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.R.C. is a co-founder of Moderna Therapeutics and Dropshot Therapeutics, a member of the board of directors of eTheRNA, and senior adviser to EQT. K.S.F. is a full-time employee of SmartCella. N.W. is a consultant for DropShot Therapeutics.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}